Send to

Choose Destination
See comment in PubMed Commons below
Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Author information

  • 1Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA
  • 2Department of Medicine, University of California, San Francisco, California, USA.
  • 3Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington, USA.
  • 4Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • 5Department of Medicine, University of Alabama, Birmingham, Alabama, USA.
  • 6Department of Medicine, University of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, New York, USA.
  • 7Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • 8Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • 9The Fenway Institute, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA.
  • 10Institute of Human Virology, University of Maryland, Baltimore, Maryland, USA.
  • 11Center for Immunization Research, Johns Hopkins University, Baltimore, Maryland, USA.
  • 12Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • 13Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA.
  • 14Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • 15Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • 16Inserm, U955, Equipe 16, Université Paris Est, Faculté de Médecine, Vaccine Research Institute (VRI), Créteil, France.
  • 17SCHARP Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • 18Bill & Melinda Gates Foundation, Seattle, Washington, USA.
  • 19AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.


Finding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 μg), ALVAC-HIV (vCP1452) alone, or 3 groups of ALVAC-HIV (vCP1452) followed by ALVAC-HIV (vCP1452) plus LIPO-5 (250, 750, and 2,500 μg). Only 73/174 participants (42%) received all four vaccinations due to a study halt related to myelitis. There were no significant differences in systemic reactions between groups or in local reactogenicity between groups receiving ALVAC-HIV (vCP1452). Significant differences in local reactogenicity occurred between groups receiving LIPO-5 (P ≤ 0.05). Gag and Env antibodies were undetectable by ELISA 2 weeks after the fourth vaccination for all but one recipient. Antibodies to Gag and Env were present in 32% and 24% of recipients of ALVAC-HIV (vCP1452) alone and in 47% and 35% of ALVAC-HIV (vCP1452)+LIPO recipients, respectively. Coadministration of LIPO-5 did not significantly increase the response rate compared to ALVAC-HIV (vCP1452) alone, nor was there a significant relationship between dose and antibody responses among ALVAC-HIV (vCP1452)+LIPO groups. Over 90% of study participants had no positive gamma interferon (IFN-γ) enzyme-linked immunosorbent spot assay (ELISpot) responses to any peptide pool at any time point. The study was halted due to a case of myelitis possibly related to the LIPO-5 vaccine; this case of myelitis remains an isolated event. In general, there was no appreciable cell-mediated immunity detected in response to the vaccines used in this study, and antibody responses were limited. The clinical trial is registered on with registry number NCT00076063.

[PubMed - indexed for MEDLINE]
Free PMC Article

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms


Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center